CAS NO: | 192329-42-3 |
包装 | 价格(元) |
1mg | 电议 |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
生物活性 | Prinomastat (AG3340) is a broad spectrum, potent, orally activemetalloproteinase (MMP)inhibitor withIC50s of 79, 6.3 and 5.0 nM forMMP-1,MMP-3andMMP-9, respectively. Prinomastat inhibitsMMP-2,MMP-3andMMP-9withKis of 0.05 nM, 0.3 nM and 0.26 nM, respectively. Prinomastat crosses blood-brain barrier. Antitumor avtivity[1][2][3][4]. | ||||||||||||
IC50& Target[1][4] |
| ||||||||||||
体外研究 (In Vitro) | Prinomastat (AG3340; 0.1-1 μg/mL; 4 days; C57MG/Wnt1 cells) inhibits Wnt1-induced MMP-3 production. Reversal of Wnt1-induced EMT and β-catenin transcriptional activity by Prinomastat[1]. Western Blot Analysis[1]
| ||||||||||||
体内研究 (In Vivo) | In a human fibrosarcoma mouse model (HT1080), the mice are treated therapeutically for 14-16 days with 50 mg/kg/day ip daily starting day 3 to 6 after tumour inoculation. Prinomastat is well tolerated by the animals, and there are no signs of weight loss or other adverse effects. Prinomastat has good tumour growth inhibition, with a short T1/2of 1.6 hours[1]. | ||||||||||||
Clinical Trial | |||||||||||||
分子量 | 423.51 | ||||||||||||
性状 | Solid | ||||||||||||
Formula | C18H21N3O5S2 | ||||||||||||
CAS 号 | 192329-42-3 | ||||||||||||
中文名称 | 普啉司他 | ||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||
储存方式 |
| ||||||||||||
溶解性数据 | In Vitro: DMSO :< 1 mg/mL (ultrasonic;warming;heat to 60℃)(insoluble or slightly soluble) |